BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 31385866)

  • 21. Cervix cytology samples revealed increased methylation of the human markers FAM19A4/miR124-2 up to 8 years before adenocarcinoma.
    Lindroth Y; Pedersen L; Alssamaray J; Berglund T; Sundqvist A; Borgfeldt C; Forslund O
    Acta Obstet Gynecol Scand; 2024 Feb; 103(2):378-386. PubMed ID: 37964497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study.
    Gori S; Battagello J; Gustinucci D; Campari C; Zorzi M; Frayle H; Passamonti B; Sartori G; Bulletti S; Fodero C; Cesarini E; Faggiano R; Del Mistro A
    BJOG; 2021 Jul; 128(8):1353-1362. PubMed ID: 33326680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methylation marker analysis and HPV16/18 genotyping in high-risk HPV positive self-sampled specimens to identify women with high grade CIN or cervical cancer.
    Verhoef VM; Heideman DA; van Kemenade FJ; Rozendaal L; Bosgraaf RP; Hesselink AT; Bekkers RL; Massuger LF; Steenbergen RD; Snijders PJ; Berkhof J; Meijer CJ
    Gynecol Oncol; 2014 Oct; 135(1):58-63. PubMed ID: 25111387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial.
    Cook DA; Krajden M; Brentnall AR; Gondara L; Chan T; Law JH; Smith LW; van Niekerk DJ; Ogilvie GS; Coldman AJ; Warman R; Reuter C; Cuzick J; Lorincz AT
    Int J Cancer; 2019 May; 144(10):2587-2595. PubMed ID: 30412281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Performance of combined liquid based cytology and HPV nucleic acid test for detecting cervical precancer among women attending screening].
    Jiang MY; Feng RM; Wang L; Li TY; Zhang AA; Cui JF; Pan QJ; Zhang X; Liu ML; Gao F; Chen W; Qiao YL
    Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):750-756. PubMed ID: 30392339
    [No Abstract]   [Full Text] [Related]  

  • 26. A Low-Cost HPV Immunochromatographic Assay to Detect High-Grade Cervical Intraepithelial Neoplasia.
    Mariano VS; Lorenzi AT; Scapulatempo-Neto C; Stein MD; Resende JC; Antoniazzi M; Villa LL; Levi JE; Longatto-Filho A; Fregnani JH
    PLoS One; 2016; 11(10):e0164892. PubMed ID: 27764154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.
    Agorastos T; Chatzistamatiou K; Katsamagkas T; Koliopoulos G; Daponte A; Constantinidis T; Constantinidis TC;
    PLoS One; 2015; 10(3):e0119755. PubMed ID: 25793281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial.
    Wright TC; Behrens CM; Ranger-Moore J; Rehm S; Sharma A; Stoler MH; Ridder R
    Gynecol Oncol; 2017 Jan; 144(1):51-56. PubMed ID: 28094038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.
    Song F; Du H; Wang C; Huang X; Wu R;
    PLoS One; 2020; 15(6):e0234518. PubMed ID: 32525936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study.
    Vink FJ; Meijer CJLM; Clifford GM; Poljak M; Oštrbenk A; Petry KU; Rothe B; Bonde J; Pedersen H; de Sanjosé S; Torres M; Del Pino M; Quint WGV; Cuschieri K; Boada EA; van Trommel NE; Lissenberg-Witte BI; Floore AN; Hesselink AT; Steenbergen RDM; Bleeker MCG; Heideman DAM
    Int J Cancer; 2020 Aug; 147(4):1215-1221. PubMed ID: 31390052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical performance of methylation as a biomarker for cervical carcinoma in situ and cancer diagnosis: A worldwide study.
    Banila C; Lorincz AT; Scibior-Bentkowska D; Clifford GM; Kumbi B; Beyene D; Wheeler CM; Cuschieri K; Cuzick J; Nedjai B
    Int J Cancer; 2022 Jan; 150(2):290-302. PubMed ID: 34562270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of HPV-positive women in cervical screening using results from two consecutive screening rounds.
    Polman NJ; Veldhuijzen NJ; Heideman DAM; Snijders PJF; Meijer CJLM; Berkhof J
    Int J Cancer; 2019 May; 144(9):2339-2346. PubMed ID: 30565673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA methylation as a triage marker for colposcopy referral in HPV-based cervical cancer screening: a systematic review and meta-analysis.
    Salta S; Lobo J; Magalhães B; Henrique R; Jerónimo C
    Clin Epigenetics; 2023 Aug; 15(1):125. PubMed ID: 37533074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus positive screening cohort.
    van Leeuwen RW; Oštrbenk A; Poljak M; van der Zee AGJ; Schuuring E; Wisman GBA
    Int J Cancer; 2019 Feb; 144(4):746-754. PubMed ID: 30259973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
    Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
    Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triaging women with human papillomavirus infection and normal cytology or low-grade dyskaryosis: evidence from 10-year follow up of the ARTISTIC trial cohort.
    Gilham C; Sargent A; Peto J
    BJOG; 2020 Jan; 127(1):58-68. PubMed ID: 31541495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
    Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
    J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lower cost strategies for triage of human papillomavirus DNA-positive women.
    Qiao YL; Jeronimo J; Zhao FH; Schweizer J; Chen W; Valdez M; Lu P; Zhang X; Kang LN; Bansil P; Paul P; Mahoney C; Berard-Bergery M; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
    Int J Cancer; 2014 Jun; 134(12):2891-901. PubMed ID: 24248915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.